期刊文献+

乙肝并肝癌患者的TACE治疗及抗病毒治疗的临床疗效观察 被引量:2

下载PDF
导出
摘要 目的观察乙肝并肝癌患者的TACE治疗及抗病毒治疗的临床疗效。方法选取我院2009年10月至2010年10月的共诊断收治的乙肝并肝癌患者200例,随机分为对照组和观察组各100例。对照组采用肝动脉化疗栓塞术(TACE)介入治疗。观察组采用TACE术后联合恩替卡韦(ETV)(0.5mg/d,口服)抗病毒治疗。疗程1年以上,2组保肝基础治疗无差异。治后观察比较2组患者肝功能、HBVDNA定量的变化及2a生存率。结果治疗后,对照组和观察组相比,肝功能(P<0.01)、观察组的HBV DNA定量的变化(P<0.01)及生存率高于对照组(P<0.05)。结论 TACE术后联合恩替卡韦(ETV)临床疗效显著,可抑制体内乙肝病毒复制,改善患者肝功能,提高生存率。
出处 《中国卫生产业》 2011年第12期135-135,共1页 China Health Industry
  • 相关文献

参考文献3

二级参考文献29

  • 1Shi, Ming,Chen, Ji-An,Lin, Xiao-Jun,Guo, Rong-Ping,Yuan, Yun-Fei,Chen, Min-Shan,Zhang, Ya-Qi,Li, Jin-Qing.Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China[J].World Journal of Gastroenterology,2010,16(2):264-269. 被引量:37
  • 2Bruix J, Sherman M. Management of hepatocellular carcinoma[J]. Hepatology,2005, 42(5): 1208-1236.
  • 3Lin H,van den Esschert J,Liu C,et al. Systematic review of hepatocellular adenoma in China and other regions[J]. J Gastroenterol Hepatol, 2011,26 ( 1 ) : 28-35.
  • 4Rahbari NN,Mehrabi A,Mollberg NM, et al. Hepatocellular carcinoma:current management and perspectives for the future [ J ]. Ann Surg, 2011,253 (3) : 453-469.
  • 5Hung IF,Poon RT,Lai CL,et al. Recurrence of hepatitis Brelated hepatocellular carcinoma is associated with high virval load at the time resection [J]. Am J Gastroenterol, 2008,103(7) : 1663-1673.
  • 6Chen G,Lin W,Shen F,et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study [J]. Am J Gastroenterol, 2006, 101 (8) : 1797-1802.
  • 7Kaibori M,Ishizaki M,Matsui K,et al. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma[J]. J Surg Onco,2010,102(5) :462-468.
  • 8Gassmann P,Spieker T,Haier J,et al. Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma [J]. World J Surg, 2010,34(10) :2442-2451.
  • 9Eguchi S, Takatsuki M, Hidaka M, et al. Predictor for histological micmvascular invasion of hepatoceUular carcinoma:a lesson from 229 consecutive cases of curative liver resection [J]. World J Surg,2010,34 (5):1034-1038.
  • 10Sun B,Karin M. NF-kappaB signaling, liver disease and hepatopmtective agents [J]. Oneogene,2008,27 (48) : 6228-2244.

共引文献20

同被引文献33

  • 1Zhong J H,Xiang B D,Gong W F,et al. Comparison of long- term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoemboli- zation[J]. PLoS 0ne,2013,8(7) :e68193.
  • 2Pefia A M, Nflfiez-Martinez 0, Diaz-Sdnchez A, et al. Transar- terial chemoembolisation in intermediate-stage hepatocellular carcinoma. Survey on clinical practice in hospitals in the Ma- drid Region[J]. Ann Hepatol,2015,14(2) : 207-217.
  • 3Jadad A R, Moore R A, Carroll D, et al. Assessing the quality of reports of randomized clinical trails: is blinding necessary [J]. Control Clin Trials, 1996,17(1) : 1-12.
  • 4刘金朵.乙型肝炎病毒相关性肝癌TACE术后抗病毒治疗的近期疗效[D].郑州:郑州大学,2014.
  • 5Yeo W,Chan P K,Zhong S,et al. Frequency of hepatitis B vi- rus reactivation in cancer patients undergoing cytotoxic chem- otherapy:a prospective study of 626 patients with identifica- tion of risk factors[J]. J Med Virol,2000,62(3):299-307.
  • 6Maluceio M, Covey A. Recent progress in understanding, diag- nosing, and treating hepatoeellular carcinoma[J]. CA Cancer J Clin, 2012,62(6) : 394-399.
  • 7李岩,阚志超,韩涛.拉米夫定联合TACE治疗原发性肝癌合并肝硬化30例[J].世界华人消化杂志,2008,16(15):1700-1703. 被引量:12
  • 8朱云杰,蔡文辉,张春英,姚长东.拉米夫定在原发性肝癌综合性介入治疗中的应用[J].肝脏,2009,14(4):346-347. 被引量:10
  • 9占国清,谭华炳,朱琳,李儒贵,张薇薇,胡波,杜卫星.抗病毒对肝动脉化疗栓塞治疗乙肝后中晚期肝癌的作用[J].临床肝胆病杂志,2010,26(4):423-424. 被引量:11
  • 10徐向东.TACE联合阿德福韦酯治疗原发性肝癌的临床观察[J].中国实用医药,2010,5(35):111-112. 被引量:7

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部